|Assessment Status||Assessment process complete|
|Indication||As an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.|
|Full pharmacoeconomic assessment commissioned by HSE||22/08/2014|
|NCPE assessment completed||25/06/2015|
|NCPE assessment outcome||Reimbursement not recommended.|
Following NCPE assessment of the company submission, omalizumab (Xolair ®) is not considered cost-effective for the treatment of severe allergic asthma and therefore is not recommended for reimbursement.